LEXINGTON, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its second quarter financial results on Thursday, July 28, 2011 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. EDT to discuss: (i) vismodegib (GDC-0449, RG3616), a hedgehog pathway inhibitor under collaboration with Genentech, (ii) CUDC-101, CUDC-907, Debio 0932 and other network-targeted cancer programs, (iii) its financial results as of and for the three- and six-month periods ended June 30, 2011, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
